Literature DB >> 7906710

Symptom profiles and homelessness in schizophrenia.

L A Opler1, C L Caton, P Shrout, B Dominguez, F I Kass.   

Abstract

One hundred homeless schizophrenic men and 100 never homeless schizophrenic men were compared in terms of symptom ratings on the Positive and Negative Syndrome Scale (PANSS), which yields a positive, negative, and general psychopathology scale score, as well as evaluated on a number of other variables. The homeless group obtained significantly higher ratings on the PANSS positive and general psychopathology scales, but the two groups did not differ on the PANSS negative scale score. When symptom patterns for subsets of patients who did not abuse illicit substances or alcohol (N = 23 for homeless, N = 56 for nonhomeless) and who were compliant with medication (N = 63 for homeless, N = 82 for nonhomeless) were examined, the higher ratings on the positive and general psychopathology scales failed to achieve statistical significance, while the absence of between-group differences on the negative scale was maintained. Our results suggest that severity of positive and general psychopathology symptoms, but not of negative symptoms, predicts homelessness in schizophrenia and that illicit substance abuse and neuroleptic noncompliance contributed, at least in part, to our higher positive and general psychopathology symptom ratings in the homeless sample. Our findings underscore the need to undertake prospective longitudinal studies to unravel the multifactorial etiology of homelessness in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906710     DOI: 10.1097/00005053-199403000-00008

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  7 in total

1.  Vestibular stimulation improves insight into illness in schizophrenia spectrum disorders.

Authors:  Philip Gerretsen; David D Pothier; Carolyn Falls; Maxine Armstrong; Thushanthi Balakumar; Hiroyuki Uchida; David C Mamo; Bruce G Pollock; Ariel Graff-Guerrero
Journal:  Psychiatry Res       Date:  2017-02-13       Impact factor: 3.222

2.  Some aspects of the cost of schizophrenia in France.

Authors:  F Rouillon; M Toumi; G Y Dansette; J Benyaya; P Auquier
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

Review 3.  Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

Authors:  K G Terkelsen; A Menikoff
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

4.  Direct costs of schizophrenia in Italian community psychiatric services.

Authors:  L Garattini; C Rossi; F Tediosi; C Cornaggia; G Covelli; C Barbui; F Parazzini
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  Part D and dually eligible patients with mental illness: medication access problems and use of intensive services.

Authors:  Haiden A Huskamp; Joyce C West; Donald S Rae; Maritza Rubio-Stipec; Darrel A Regier; Richard G Frank
Journal:  Psychiatr Serv       Date:  2009-09       Impact factor: 3.084

6.  Treatment-refractory schizophrenia.

Authors:  Asaf Caspi; Michael Davidson; Carol A Tamminga
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

7.  Psychiatric morbidity of overseas patients in inner London: A hospital based study.

Authors:  Fredy J Carranza; Alice M Parshall
Journal:  Ann Gen Psychiatry       Date:  2005-02-14       Impact factor: 3.455

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.